As had long been expected, Novartis has announced plans to hive off its generics business, Sandoz, creating a new publicly-traded company. 25 August 2022
A woman who has been involved in biosimilars since work on their development first began two decades ago, has been named director general of the International G 21 February 2019
Daniel Gallagher – who from November 2011 to October 2015 was commissioner of the US Securities and Exchange Commission (SEC) – has joined Netherlands-incorpora 28 March 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.